# A Long-Term Extension Trial From Late Phase II of SPM 962 in Patients With Restless Legs Syndrome

> **NCT01562743** · PHASE2 · COMPLETED · sponsor: **Otsuka Pharmaceutical Co., Ltd.** · enrollment: 185 (actual)

## Conditions studied

- Idiopathic Restless Legs Syndrome

## Interventions

- **DRUG:** SPM 962

## Key facts

- **NCT ID:** NCT01562743
- **Lead sponsor:** Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-08
- **Primary completion:** 2010-10
- **Final completion:** 2010-10
- **Target enrollment:** 185 (ACTUAL)
- **Last updated:** 2014-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01562743

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01562743, "A Long-Term Extension Trial From Late Phase II of SPM 962 in Patients With Restless Legs Syndrome". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT01562743. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*